Thromboembolism in a patient with a mechanical mitral valve during anticoagulation with dabigatran etexilate.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 24182477.
- Also identified by DOI 10.1016/j.athoracsur.2013.03.043.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Recently, several new anticoagulants have been used instead of warfarin for preventing thromboembolism. In the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial, the direct thrombin inhibitor dabigatran etexilate was as an effective and safe as dose-adjusted warfarin for prevention of stroke in high-risk patients with atrial fibrillation. However, the safety and efficacy of thromboprophylaxis after mechanical valve replacement is uncertain. We report a 57-year-old man with a mechanical heart valve who experienced acute upper limb thromboembolism during dabigatran intake. Dabigatran might be inadequate for thromboprophylaxis after mechanical valve replacement.
Medical subject headings
- Anticoagulants
- Antithrombin Proteins
- Benzimidazoles
- Heart Valve Prosthesis
- Mitral Valve
- Pyridines
- Thromboembolism